Amgen Inc. $AMGN Shares Purchased by Aviance Capital Partners LLC

Aviance Capital Partners LLC boosted its position in Amgen Inc. (NASDAQ:AMGN) by 10.7% in the fourth quarter, HoldingsChannel.com reports. The firm owned 36,980 shares of the medical research company’s stock after purchasing an additional 3,566 shares during the quarter. Amgen comprises approximately 1.4% of Aviance Capital Partners LLC’s investment portfolio, making the stock its 11th biggest holding. Aviance Capital Partners LLC’s holdings in Amgen were worth $12,104,000 as of its most recent SEC filing.

A number of other institutional investors have also recently added to or reduced their stakes in the company. Vanguard Group Inc. lifted its position in Amgen by 1.8% in the fourth quarter. Vanguard Group Inc. now owns 54,838,826 shares of the medical research company’s stock worth $17,949,296,000 after purchasing an additional 961,975 shares during the period. Capital International Investors lifted its position in Amgen by 1.5% in the third quarter. Capital International Investors now owns 19,192,995 shares of the medical research company’s stock worth $5,414,296,000 after purchasing an additional 282,219 shares during the period. Capital World Investors lifted its position in shares of Amgen by 11.5% during the 3rd quarter. Capital World Investors now owns 18,795,474 shares of the medical research company’s stock valued at $5,303,578,000 after acquiring an additional 1,935,876 shares during the last quarter. Capital Research Global Investors lifted its position in shares of Amgen by 2.7% during the 3rd quarter. Capital Research Global Investors now owns 4,731,290 shares of the medical research company’s stock valued at $1,335,168,000 after acquiring an additional 122,631 shares during the last quarter. Finally, Invesco Ltd. lifted its position in shares of Amgen by 6.6% during the 3rd quarter. Invesco Ltd. now owns 4,467,287 shares of the medical research company’s stock valued at $1,260,668,000 after acquiring an additional 277,031 shares during the last quarter. 76.50% of the stock is currently owned by institutional investors and hedge funds.

Insider Transactions at Amgen

In other Amgen news, SVP Nancy A. Grygiel sold 1,237 shares of the business’s stock in a transaction on Monday, May 4th. The shares were sold at an average price of $323.73, for a total transaction of $400,454.01. Following the sale, the senior vice president directly owned 7,009 shares of the company’s stock, valued at $2,269,023.57. The trade was a 15.00% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. 0.85% of the stock is currently owned by company insiders.

Amgen Price Performance

Shares of NASDAQ:AMGN opened at $324.39 on Tuesday. The company’s fifty day moving average is $348.31 and its two-hundred day moving average is $343.59. The company has a quick ratio of 1.01, a current ratio of 1.26 and a debt-to-equity ratio of 5.65. Amgen Inc. has a 12-month low of $267.83 and a 12-month high of $391.29. The company has a market cap of $175.07 billion, a P/E ratio of 22.57, a price-to-earnings-growth ratio of 3.28 and a beta of 0.44.

Amgen (NASDAQ:AMGN) last announced its earnings results on Thursday, April 30th. The medical research company reported $5.15 earnings per share (EPS) for the quarter, beating the consensus estimate of $4.77 by $0.38. Amgen had a net margin of 20.96% and a return on equity of 137.41%. The company had revenue of $8.62 billion for the quarter, compared to the consensus estimate of $8.58 billion. During the same period in the previous year, the business earned $4.90 EPS. The company’s revenue was up 5.8% on a year-over-year basis. Amgen has set its FY 2026 guidance at 21.700-23.100 EPS. Equities analysts expect that Amgen Inc. will post 22.37 earnings per share for the current fiscal year.

Amgen Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Friday, June 5th. Shareholders of record on Friday, May 15th will be paid a dividend of $2.52 per share. This represents a $10.08 annualized dividend and a yield of 3.1%. The ex-dividend date of this dividend is Friday, May 15th. Amgen’s payout ratio is 70.15%.

Analysts Set New Price Targets

A number of equities research analysts have recently commented on the company. Citigroup increased their price objective on Amgen from $315.00 to $345.00 and gave the company a “neutral” rating in a research report on Wednesday, February 4th. Piper Sandler cut their price objective on Amgen from $432.00 to $427.00 and set an “overweight” rating for the company in a research report on Thursday. Barclays assumed coverage on Amgen in a research report on Friday, February 20th. They set an “equal weight” rating and a $350.00 price objective for the company. Leerink Partners reiterated a “market perform” rating and set a $355.00 price objective on shares of Amgen in a research report on Thursday, March 5th. Finally, Truist Financial increased their price objective on Amgen from $325.00 to $327.00 and gave the company a “hold” rating in a research report on Friday, May 1st. Two research analysts have rated the stock with a Strong Buy rating, thirteen have given a Buy rating, fourteen have given a Hold rating and two have given a Sell rating to the company. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Hold” and an average target price of $356.15.

About Amgen

Amgen Inc (NASDAQ: AMGN) is a global biotechnology company founded in 1980 and headquartered in Thousand Oaks, California. The company focuses on discovering, developing, manufacturing and delivering human therapeutics that address serious illnesses. Amgen’s work centers on biologic medicines derived from cellular and molecular biology, with an emphasis on translating advances in human genetics and protein science into therapies for patients.

Amgen’s commercial portfolio has historically included biologics used in oncology, supportive care, nephrology, bone health and cardiovascular disease.